Association between menopausal estrogen-only therapy and ovarian carcinoma risk

Obstetrics and Gynecology

Volumn 127, Issue 5, 2016, Pages 828-836

  Lee, Alice W ^a   Ness, Roberta B ^a   Roman, Lynda D ^a   Terry, Kathryn L ^a   Schildkraut, Joellen M ^a   Chang Claude, Jenny ^a   Doherty, Jennifer A ^a   Menon, Usha ^a   Cramer, Daniel W ^a   Gayther, Simon A ^a   Risch, Harvey ^a   Gentry Maharaj, Aleksandra ^a   Goodman, Marc T ^a   Modugno, Francesmary ^a   Eilbe, Ursula ^a   Moysich, Kirsten B ^a   Berchuck, Andrew ^a   Rossing, Mary Anne ^a   Jensen, Allan ^a   Wicklund, K G ^a   Cushing Haugen, Kara L ^a   Hogdall, Estrid ^a   Rudolph, Anja ^a   Thompson, Pamela J ^a   Wilkens, Lynne R ^a   Kjaer, Susanne K ^a   Carney, Michael E ^a   Stram, Daniel O ^a   Ramus, S J ^a   Wu, Anna H ^a   Pike, Malcolm C ^a   Pearce, Celeste Leigh ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN;

ADULT; AGED; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; ENDOMETRIOID CARCINOMA; ESTROGEN THERAPY; FEMALE; HUMAN; HYSTERECTOMY; MENOPAUSE; MIDDLE AGED; OVARY CARCINOMA; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; RISK FACTOR; SELF REPORT; TIME TO TREATMENT; TREATMENT DURATION; ADVERSE EFFECTS; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; OVARIAN NEOPLASMS; UNITED STATES;

CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MENOPAUSE; OVARIAN NEOPLASMS; RISK ASSESSMENT; SURVEYS AND QUESTIONNAIRES; UNITED STATES;

EID: 84992499898     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000001387     Document Type: Article

References (35)

1. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
2. Collaborative Group On Epidemiological Studies Of Ovarian Cancer, Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, Peto R. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 2015;385:1835-42.
3. Pearce CL, Chung K, Pike MC, Wu AH. Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin. Cancer 2009;115:531-9.
4. Morch LS, Løkkegaard E, Andreasen AH, Krüger-Kjaer S, Lidegaard O. Hormone therapy and ovarian cancer. JAMA 2009;302:298-305.
5. Tsilidis KK, Allen NE, Key TJ, Dossus L, Kaaks R, Bakken K, et al. Menopausal hormone therapy and risk of ovarian cancer in the European prospective investigation into cancer and nutrition. Cancer Causes Control 2011;22:1075-84.
6. Hildebrand JS, Gapstur SM, Feigelson HS, Teras LR, Thun MJ, Patel AV. Postmenopausal hormone use and incident ovarian cancer: Associations differ by regimen. Int J Cancer 2010;127: 2928-35.
7. Beral V; Million Women Study Collaborators, Bull D, Green J, Reeves G. Ovarian cancer and hormone replacement therapy in the million women study. Lancet 2007;369:1703-10.
8. Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 2002;94:497-504.
9. Moorman PG, Schildkraut JM, Calingaert B, Halabi S, Berchuck A. Menopausal hormones and risk of ovarian cancer. Am J Obstet Gynecol 2005;193:76-82.
10. Royar J, Becher H, Chang-Claude J. Low-dose oral contraceptives: protective effect on ovarian cancer risk. Int J Cancer 2001;95:370-4.
11. Balogun N, Gentry-Maharaj A, Wozniak EL, Lim A, Ryan A, Ramus SJ, et al. Recruitment of newly diagnosed ovarian cancer patients proved challenging in a multicentre biobanking study. J Clin Epidemiol 2011;64:525-30.
12. Lurie G, Terry KL, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, et al. Pooled analysis of the association of PTGS2 rs5275 polymorphism and NSAID use with invasive ovarian carcinoma risk. Cancer Causes Control 2010;21:1731-41.
13. Ness RB, Dodge RC, Edwards RP, Baker JA, Moysich KB. Contraception methods, beyond oral contraceptives and tubal ligation, and risk of ovarian cancer. Ann Epidemiol 2011;21:188-96.
14. Moorman PG, Calingaert B, Palmieri RT, Iversen ES, Bentley RC, Halabi S, et al. Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women. Am J Epidemiol 2008;167:1059-69.
15. Wu AH, Pearce CL, Tseng CC, Templeman C, Pike MC. Markers of inflammation and risk of ovarian cancer in Los Angeles County. Int J Cancer 2009;124:1409-15.
16. Terry KL, De Vivo I, Titus-Ernstoff L, Shih MC, Cramer DW. Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk. Cancer Res 2005;65: 5974-81.
17. Pike MC, Pearce CL, Peters R, Cozen W, Wan P, Wu AH. Hormonal factors and the risk of invasive ovarian cancer: a population- based case-control study. Fertil Steril 2004;82:186-95.
18. Bodelon C, Cushing-Haugen KL, Wicklund KG, Doherty JA, Rossing MA. Sun exposure and risk of epithelial ovarian cancer. Cancer Causes Control 2012;23:1985-94.
19. Risch HA, Bale AE, Beck PA, Zheng W. PGR +331 A/G and increased risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2006;15:1738-41.
20. Glud E, Kjaer SK, Thomsen BL, Høgdall C, Christensen L, Høgdall E, et al. Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. Arch Intern Med 2004; 164:2253-9.
21. Beral V, Bull D, Reeves G; Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005;365:1543-51.
22. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85:304-13.
23. Morabia A, Costanza MC. International variability in ages at menarche, first livebirth, and menopause. World Health Organization collaborative study of neoplasia and steroid contraceptives. Am J Epidemiol 1998;148:1195-205.
24. Pike MC. Age-related factors in cancers of the breast, ovary, and endometrium. J Chronic Dis 1987;40(suppl 2):59S-69S.
25. Kumar VCR, Robbins SL. Basic pathology. 6th ed. Philadelphia (PA): W.B. Saunders; 1997.
26. Danforth KN, Tworoger SS, Hecht JL, Rosner BA, Colditz GA, Hankinson SE. A prospective study of postmenopausal hormone use and ovarian cancer risk. Br J Cancer 2007;96:151-6.
27. Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 2012;13:385-94.
28. Ho SM. Estrogen, progesterone and epithelial ovarian cancer. Reprod Biol Endocrinol 2003;1:73.
29. Zhou H, Luo MP, Schonthal AH, Pike MC, Stallcup MR, Blumenthal M, et al. Effect of reproductive hormones on ovarian epithelial tumors: I. Effect on cell cycle activity. Cancer Biol Ther 2002;1:300-6.
30. Donnez J, Casanas-Roux F, Caprasse J, Ferin J, Thomas K. Cyclic changes in ciliation, cell height, and mitotic activity in human tubal epithelium during reproductive life. Fertil Steril 1985;43:554-9.
31. George SH, Milea A, Shaw PA. Proliferation in the normal FTE is a hallmark of the follicular phase, not BRCA mutation status. Clin Cancer Res 2012;18:6199-207.
32. Nash JD, Ozols RF, Smyth JF, Hamilton TC. Estrogen and antiestrogen effects on the growth of human epithelial ovarian cancer in vitro. Obstet Gynecol 1989;73:1009-16.
33. Laviolette LA, Hodgkinson KM, Minhas N, Perez-Iratxeta C, Vanderhyden BC. 17b-estradiol upregulates GREB1 and accelerates ovarian tumor progression in vivo. Int J Cancer 2014; 135:1072-84.
34. Sandini L, Pentti K, Tuppurainen M, Kroger H, Honkanen R. Agreement of self-reported estrogen use with prescription data: an analysis of women from the Kuopio Osteoporosis Risk Factor and Prevention Study. Menopause 2008;15:282-9.
35. Paganini-Hill A, Clark LJ. Comparison of patient recall of hormone therapy with physician records. Menopause 2007;14: 230-4.